Health Canada has recently announced that they will no longer be covering the cost of the COVID-19 treatment drug, Paxlovid, leaving Albertans responsible for the bill.
The decision was made after Health Canada reviewed the effectiveness and cost of the drug, which has been shown to reduce hospitalizations and deaths in COVID-19 patients. However, the high price tag of $2,000 per treatment course was deemed too expensive for the government to cover.
This news comes as a disappointment to many Albertans who were relying on the coverage of Paxlovid to help them in case of a COVID-19 infection. The drug has been hailed as a potential game-changer in the fight against the pandemic, with promising results in clinical trials.
According to Health Canada, the decision to drop coverage for Paxlovid was not an easy one, but it was necessary to ensure the sustainability of the healthcare system. The cost of the drug would have put a strain on the already stretched resources of the government, especially with the ongoing pandemic.
However, this decision has sparked criticism from healthcare professionals and patients alike. They argue that the cost of Paxlovid should not be a barrier to accessing life-saving treatment, especially during a global health crisis.
In response to the backlash, Health Canada has stated that they are open to reviewing their decision if the manufacturer of Paxlovid, Pfizer, can lower the price of the drug. They have also urged the provincial government to negotiate with the company to make the drug more affordable for Albertans.
In the meantime, Albertans who require Paxlovid treatment will have to pay for it out of pocket. This news serves as a reminder of the importance of having a comprehensive and accessible healthcare system, especially during times of crisis.
As the situation continues to evolve, it is crucial for the government and pharmaceutical companies to work together to find a solution that benefits the health and well-being of all Canadians.
